XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Q3 2026 | -0.01 | 0.02 | +300.00% | $206.7M | ✅ Beat | +2.63% | +9.93% | +0.33% |
| 2026-01-08 | Q2 2026 | -0.06 | 0.01 | +116.67% | $217.5M | ✅ Beat | — | — | — |
| 2025-10-09 |
| Q1 2026 |
| -0.01 |
| 0.00 |
| +100.00% |
| $209.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-28 | Q4 2025 | -0.01 | 0.02 | +300.00% | $224.5M | ✅ Beat | -7.07% | -13.13% | +95.80% |
| 2025-04-08 | Q3 2025 | -0.03 | 0.00 | +100.00% | $185.8M | ✅ Beat | +16.17% | +3.62% | -3.07% |
| 2025-01-10 | Q2 2025 | -0.01 | 0.00 | +100.00% | $210.9M | ✅ Beat | -4.07% | -2.44% | -20.28% |
| 2024-10-10 | Q1 2025 | -0.04 | -0.01 | +75.00% | $200.0M | ✅ Beat | +2.52% | -1.26% | -11.95% |
| 2024-07-29 | Q4 2024 | -0.02 | 0.04 | +300.00% | $229.9M | ✅ Beat | +9.84% | -5.46% | -7.10% |
Showing last 8 quarters.